Whoop
A 45-biomarker comprehensive health panel inspired by WHOOP Advanced Labs — a deep look at metabolism, cardiovascular risk, hormones, liver, kidney and inflammation.
Cholesterol travels in your blood in particles, and Lp(a) is one of them: an LDL particle with an extra protein attached, apolipoprotein(a). According to the European Atherosclerosis Society (EAS), Lp(a) can set off inflammation in the arterial wall.
The higher your Lp(a), the greater the risk of cardiovascular disease according to the EAS, with no sharp cut-off, and that level is more than 90% set in your genes. Only a blood test shows how much Lp(a) you have.
Unilabs expresses Lp(a) in nanomoles per litre (nmol/l) and divides the result for cardiovascular disease into three: below 75 nmol/l rule out, 75 to 125 nmol/l a grey zone, and above 125 nmol/l rule in.
Doctor's Assessment Included
Lp(a) is a fat particle whose level is largely inherited. Laboratories report it in nmol/l or mg/l, so a result can only be compared with the limit of the laboratory that measured it.
| Result | Value (g/l) |
|---|---|
| Normal | < 0,3 |
| Borderline | 0,3–0,5 |
| Elevated | ≥ 0,5 |
Lp(a) is largely inherited and stays almost constant throughout life. The risk rises gradually with the value; the EAS stresses that there is no biological threshold. The NHG guideline CVRM uses > 50 mg/dl (0.50 g/l, 80th percentile) as the cut-off and advises against screening the general population. Some laboratories apply a stricter upper limit (0.3 g/l), which matches the lower end of the EAS grey zone.
Source: Nederlands Huisartsen Genootschap Reference population: Adults (NHG guideline CVRM; EAS 2022)
Source: European Atherosclerosis Society Reference population: Adults (NHG guideline CVRM; EAS 2022)
Reference ranges may vary between laboratories. When you order a test, a BIG-registered doctor assesses your personal results in context. For treatment decisions, discuss your results with your GP.
The upper limit runs from 60 nmol/l at Unilabs to 75 nmol/l at Star-shl.
| Laboratory | Group | Reference value (nmol/l) | Relative scale |
|---|---|---|---|
| Star-shl | · Everyone · a limit, not a range | < 75 nmol/l |
75
|
| Unilabs | · Everyone · a limit, not a range | < 60 nmol/l |
60
|
| Unilabs | · Everyone · grey zone for cardiovascular disease | 75–125 nmol/l |
75 125
|
| Unilabs | · Everyone · a limit, not a range · raised risk of cardiovascular disease | > 125 nmol/l |
125
|
| Certe | · Everyone · 18 years and older · a limit, not a range | < 500 mg/L mg/L | |
| Certe | · Everyone · grey zone | 300–500 mg/L mg/L | |
| Certe | · Everyone · a limit, not a range · high risk | > 500 mg/L mg/L | |
| Diagnostiek voor U | · Everyone · a limit, not a range | < 75 nmol/L |
75
|
Source: Star-shl
Source: Unilabs
Source: Certe
Source: Diagnostiek voor U
Each value as the laboratory itself publishes it, retrieved in 2026.
Star-SHL and Unilabs report the concentration of Lp(a) in your serum in nanomoles per litre (nmol/l). Star-SHL measures with immunoturbidimetry and gives < 75 nmol/l as the reference value, Unilabs < 60 nmol/l.
The EAS describes Lp(a) as a cause of cardiovascular disease whose risk is continuous, with a rising risk already below the usual limits. The EAS advises reading the result within your total risk of cardiovascular disease.
The guidelines differ on measuring Lp(a): the 2022 EAS consensus says at least once in every adult, preferably with the first lipid profile, while the Dutch guideline on inherited dyslipidaemia sees no justification for screening the whole population. That Dutch guideline does call a measurement worth considering with unexplained cardiovascular disease at a young age, in yourself or in the family.
A low Lp(a) falls within the reference values of Star-SHL (< 75 nmol/l) and Unilabs (< 60 nmol/l); neither laboratory gives a lower limit.
A high Lp(a) raises your risk of cardiovascular disease according to the EAS, and that risk increases gradually as the value rises. According to the EAS, a causal link with thrombosis in the veins has not been shown.
Reduced liver function
Lp(a) is made in the liver, so a poorly working liver can lower the level.
Overactive thyroid
An overactive thyroid can lower Lp(a); after treatment the level rises by 20 to 25 percent.
Hormone therapy after menopause
Hormone replacement therapy after menopause lowers Lp(a) by about 25 percent.
Severe acute illness
In life-threatening conditions such as sepsis or severe burns, Lp(a) is lower.
Inherited level
The Lp(a) level is thought to be mainly set by the genes and to barely change from adulthood.
Kidney disease
Reduced kidney function can raise Lp(a), and in nephrotic syndrome the level is 3 to 5 times higher.
Pregnancy
Lp(a) can double during pregnancy.
Underactive thyroid
An underactive thyroid can raise Lp(a); treatment lowers it by 5 to 20 percent.
If a parent, brother or sister has a markedly raised Lp(a), the EAS considers it reasonable to measure your Lp(a) too. The EAS recommends family testing for high Lp(a) with familial hypercholesterolaemia (inherited high cholesterol), with a (very) high Lp(a) in the family, and with cardiovascular disease in yourself or in the family.
According to the EAS, Lp(a) should be measured at least once in adults, and the Dutch guideline on inherited dyslipidaemia assumes that the value hardly changes from adulthood.
According to the EAS, Lp(a) falls by 15 to 30% with PCSK9 inhibitors, which are not registered for that, and new medicines against the production of apo(a) are being studied. Whether lowering Lp(a) specifically leads to less cardiovascular disease has not yet been examined in any randomised study, according to the Dutch guideline on inherited dyslipidaemia.
Unilabs calls an Lp(a) of 75 to 125 nmol/l a grey zone for cardiovascular disease: below 75 nmol/l Unilabs counts the risk as ruled out, above 125 nmol/l as ruled in.
This marker is included in the following test panels.
A 45-biomarker comprehensive health panel inspired by WHOOP Advanced Labs — a deep look at metabolism, cardiovascular risk, hormones, liver, kidney and inflammation.
A 46-biomarker heart health panel inspired by the WHOOP Heart Health Panel — an advanced look at cholesterol, lipoproteins, inflammation and kidney function.
A 49-biomarker men's health panel inspired by the WHOOP Men's Health Panel — testosterone, PSA and prostate health plus a complete metabolic and hormone base.
A 51-biomarker performance panel inspired by the WHOOP Performance Health Panel — recovery, blood production, thyroid, hormones, iron and nutrient status for people who train.
Medical reviewer
Dr. Naimi oversees the medical standards behind our content and assessments.
Medical policyDoctor's Assessment Included
Every result includes a professional assessment from a BIG-registered doctor. For treatment decisions, discuss your results with your GP.
Lipoprotein(a)
€36,-
We use cookies to analyze site usage and measure ad effectiveness. Privacy Policy